Havrix (hepatitis A vaccine, inactivated) / GSK - LARVOL DELTA

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination against Hepatitis A 9 to 11 Years after Its Implementation in the Tyva Republic, the Russian Federation. (PubMed, Vaccines (Basel)) - "The anti-HAV IgG antibodies were determined in two independent cohorts of children who were vaccinated with a single dose of monovalent pediatric inactivated vaccine (HAVRIX® 720 EU) in Tyva in 2012 and recruited 9 years (Year 9 Cohort) and 11 years (Year 11 Cohort) after immunization...However, the limited monitoring of HAV RNA in sewage and environmental samples demonstrated the ongoing circulation of both the regional epidemic strain of HAV genotype IA and another genotype IA strain imported recently from other parts of the Russian Federation, probably due to subclinical infections in non-vaccinated children under 3 years of age. Taken together, these data indicate the effectiveness of the single-dose HAV vaccination strategy but suggest the need to expand the vaccination program to include children aged 12 months and older to achieve maximum effectiveness."

Journal • Hepatology • Infectious Disease • Inflammation • Pediatrics

HAV-RCT: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (clinicaltrials.gov) - P3 | N=120 | Active, not recruiting | Sponsor: Chiang Mai University | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Head-to-Head • Hepatology • Infectious Disease • Inflammation

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Mahidol University | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation

HAV-RCT: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Chiang Mai University

Head-to-Head • New P3 trial • Hepatology • Infectious Disease • Inflammation

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Mahidol University

New P4 trial • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (clinicaltrials.gov) - P4 | N=129 | Active, not recruiting | Sponsor: Oregon Health and Science University | Recruiting ➔ Active, not recruiting | N=400 ➔ 129 | Trial primary completion date: Aug 2024 ➔ Jan 2025

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Psoriatic Arthritis • Rheumatology • IL17A • IL23A

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (clinicaltrials.gov) - P3 | N=2637 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Sep 2023 | Trial primary completion date: Oct 2024 ➔ Sep 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections • Pediatrics

Immunogenicity and safety of Havisure vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study. (PubMed, Vaccine) - "The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine."

Clinical • Head-to-Head • Journal • P2/3 data • Hepatology • Infectious Disease • Inflammation • Pain

Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study. (PubMed, Emerg Microbes Infect) - "PLWH included in the study received either Havrix or Vaqta. The seroprotection against HAV remained high in the long-term follow-up among PLWH on antiretroviral therapy after 2-dose HAV vaccination. Regular monitoring of seroresponses and timely administration of HAV vaccines are warranted to maintain seroprotection."

Journal • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

"we use havrix :)" (@DrDadSays)

VITHA-C: To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (clinicaltrials.gov) - P3 | N=119 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Unknown status ➔ Completed

Trial completion • Hepatology • Infectious Disease • Inflammation

Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults. (PubMed, Vaccine) - "Inactivated aluminum-adsorbed hepatitis A vaccines such as Havrix, Vaqta, and Avaxim are commonly used worldwide. Registered 03 April 2014. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015906."

Journal • Hepatology • Infectious Disease • Inflammation

Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction. (PubMed, Hum Vaccin Immunother) - "Compared to Havrix®, the vaccine Healive® showed a stronger protective effect and better persistence among children at 15 years post-full immunization. Prediction indicated at least 30 years of antibody persistence for Healive® and at least 25 years for Havrix®."

Journal • Hepatology • Infectious Disease • Inflammation

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (clinicaltrials.gov) - P2 | N=1301 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Malaria

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (clinicaltrials.gov) - P3 | N=2628 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Oct 2023 ➔ Oct 2024 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections • Pediatrics

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs (clinicaltrials.gov) - P3 | N=106 | Not yet recruiting | Sponsor: Boryung Biopharma Co., Ltd.

New P3 trial • Hepatology • Infectious Disease • Inflammation

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Pneumococcal Infections • Respiratory Diseases • Tetanus • Varicella Zoster

Expanded table: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus • Varicella Zoster

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (clinicaltrials.gov) - P3 | N=2628 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections • Pediatrics

Impacts of Systematically Screening All Blood Donations for Parvovirus B19 and Hepatitis A Using Nucleic Acid Tests (AABB 2022) - "Neither of them had travelled nor had risk factors for hepatitis A. They all had a recent history of hepatitis A vaccination in the days prior to the donation (Havrix: 2 days and 1 day, Twinrix: 6 days). The rate of parvovirus B19 positivity was much lower than expected, possibly because of the sanitary measures during the SARS-CoV-2 pandemic. The three individuals who tested positive for hepatitis A were presumably false positives due to recent vaccination with inactivated viral strains. We introduced a seven-day deferral after HAV vaccination to minimize the negative impacts of false-positive results."

Genetic Disorders • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Sickle Cell Disease

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (clinicaltrials.gov) - P4 | N=400 | Recruiting | Sponsor: Oregon Health and Science University

New P4 trial • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Psoriatic Arthritis • Rheumatology • IL17A • IL23A